Why the study?
This study aimed to evaluate the diagnostic performance of ultrasound-derived fat fraction for MASLD by comparing it directly with MRI-PDFF and CAP.
Does ultrasound-derived fat fraction (UDFF) accurately diagnose metabolic dysfunction-associated steatotic liver disease (MASLD) compared to MRI-PDFF in adults?
Population
103 individuals, including 53 MASLD patients and 49 healthy controls
Comparison
UDFF vs MRI-PDFF vs CAP
Design
Diagnostic study
Key result
Ultrasound-derived fat fraction demonstrated high diagnostic accuracy for detecting hepatic steatosis with an AUC of 0.981, which was significantly superior to the controlled attenuation parameter.
Authors
Loading...
May support point-of-care MASLD screening; leaves open prospective validation versus MRI-PDFF.
Cross-Sectional (n=103)
Triple-blind
No
Does ultrasound-derived fat fraction (UDFF) accurately diagnose metabolic dysfunction-associated steatotic liver disease (MASLD) compared to MRI-PDFF in adults?
Effect estimate: AUC 0.981 (95% CI 0.961-1.000)
Absolute Event Rate: 0.981% vs 0.932%
p-value: p=<0.001
Ultrasound-derived fat fraction (UDFF) provides a highly accurate, non-invasive alternative to MRI-PDFF for diagnosing metabolic dysfunction-associated steatotic liver disease, outperforming the established CAP method.
Jin et al. (2025) conducted a cross-sectional in Metabolic dysfunction-associated steatotic liver disease (MASLD) (n=103). Ultrasound-derived fat fraction (UDFF) vs. Controlled attenuation parameter (CAP) was evaluated on Diagnostic performance (AUC) for predicting MRI-PDFF ≥ 5% (AUC 0.981, 95% CI 0.961-1.000, p=<0.001). Ultrasound-derived fat fraction demonstrated high diagnostic accuracy for detecting hepatic steatosis with an AUC of 0.981, which was significantly superior to the controlled attenuation parameter.